A CYP2C9 gene polymorphism has been associated with increased susceptibility to colorectal cancer and adenoma 39, increased progression of nonalcoholic fatty liver disease 40, and excessive anticoagulation and bleeding risk in patients taking warfarin 41. This evidence concerns the gene CYP2C9 and metabolic dysfunction-associated steatotic liver disease.